DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Renin-Guided Therapeutics in the Management of Untreated, Uncontrolled, or Complicated Hypertension

Information source: Medical University of South Carolina
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Hypertension

Intervention: clinical hypertension specialist-no specific med. Any anti-hypertension meds. (Drug); renin guided therapeutics-no specific med. Any anti-hypertensive med. (Drug)

Phase: N/A

Status: Completed

Sponsored by: Medical University of South Carolina

Summary

Plasma renin values determine whether volume or vasoconstrictor (renin) factors predominate in elevating blood pressure and are useful in selecting effective antihypertensive therapy. 2,3

The researchers hypothesize that:

1. Plasma renin-guided therapeutics will improve systolic and diastolic blood pressure control in patients with untreated hypertension as well as in patients with treatment refractory or resistant hypertension that are managed by Clinical Hypertension Specialists.

2. Renin-guided therapeutics will reduce the number of medications required to maintain blood pressure control to <140/90 mmHg in hypertensive patients receiving 3 or more medications, while under the care of a Clinical Hypertension Specialist.

3. Renin-guided therapeutics selection will reduce the total cost of antihypertensive care provided by Clinical Hypertension Specialists.

Clinical Details

Official title: Renin-Guided Therapeutics in the Management of Untreated, Uncontrolled or Complicated Hypertension

Study design: Treatment, Non-Randomized, Open Label, Parallel Assignment

Detailed description: Hypertension affects ~25% of adults. The prevalence of hypertension and related complications is greater among the elderly, obese, and ethnic minorities. Unfortunately, hypertension control rates remain in the 25% range and are often significantly lower for the high-risk groups noted. 1 Since the high-risk groups are growing more rapidly than the general population, the prevalence of hypertension and associated morbidity and mortality will probably increase sharply in the years ahead unless successful strategies are implemented for dramatically improving blood pressure control.

Direct measurements of plasma renin reflect the relative balance between volume (V) and vasoconstrictor (renin [R]) factors underlying the elevated blood pressure in patients with essential hypertension. 2 While many antihypertensive medications have effects on both the volume (V) and vasoconstrictor (renin [R]) components of elevated blood pressure, one or the other usually predominates

Eligibility

Minimum age: 21 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Age, 21 years of age and older

- Male or female (post-menopausal or effective method of birth control)

- BP and treatment criteria noted above

- Willingness to provide written, informed consent

- Ability to adhere to study protocol

Exclusion Criteria:

- Uncontrolled diabetes or hyperlipidemia requiring medication changes

- Any active disease process requiring new diagnostic and therapeutic plans

- Any life-threatening illness

- History of alcohol or drug abuse in past 5 years

- Mental illness or personality disorder that interfere with adherence to study

protocol

- Serum creatinine >2. 5 mg/dL unless documented stable for at least one year

- Dialysis for chronic renal failure, even if creatinine stable for at least one year

- Intolerance to two or more classes of antihypertensive medications

- Normal home BP (<140/90 mmHg at baseline), i. e., office only hypertension.

Locations and Contacts

Additional Information

Starting date: September 2003
Ending date: September 2005
Last updated: May 22, 2008

Page last updated: June 20, 2008

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2012